EMA Application withdrawn: Arxxant — Eli Lilly Nederland B.V.

View source ↗

Summary

The EMA withdrew the application for Arxxant by Eli Lilly Nederland B.V. for diabetic retinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Drugs mentioned

• ARXXANT

Snippet

Status: Application withdrawn. Therapeutic area: Diabetic Retinopathy. MAH: Eli Lilly Nederland B.V.. Decision date: 31/12/2009